Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30637
Abstract: The addition of irinotecan to an epidermal growth factor receptor (EGFR) antibody has previously been shown to improve tumor response rate and time to progression but not overall survival (OS) for refractory metastatic colorectal cancer… read more here.
Keywords: metastatic colorectal; colorectal cancer; cetuximab plus; ontario canada ... See more keywords
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey
Sign Up to like & getrecommendations! Published in 2017 at "Oncology"
DOI: 10.1159/000454732
Abstract: Background: The cetuximab plus platinum-based chemotherapy regimen is a standard of care in the treatment of recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The feasibility in the elderly population is currently unknown. Methods:… read more here.
Keywords: recurrent metastatic; chemotherapy regimen; metastatic head; cetuximab ... See more keywords
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "AntiCancer Research"
DOI: 10.21873/anticanres.15395
Abstract: Background/Aim: This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma… read more here.
Keywords: plus paclitaxel; weekly cetuximab; recurrent metastatic; oral squamous ... See more keywords
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cancer"
DOI: 10.7150/jca.19458
Abstract: Background: Anti-EGFR therapies have been recommended for advanced colorectal cancer (CRC) with wild-type RAS and PIK3CA mutation. However, PIK3CA mutations are a poor prognostic marker and a negative predictor of response to anti-EGFR therapies in… read more here.
Keywords: type ras; ras pik3ca; pik3ca mutation; cetuximab plus ... See more keywords